Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/ Gynecologic Oncology Group Study 0229N
Endometrial adenocarcinoma (EMC) is the most common of all uter- ine malignancies and is the most common gynecologic malignancy in the US estimated to affect 52,630 women and to result in 8590 deaths in 2014.
